Flu rebound refers to a return of fever or symptoms after an initial period of improvement during an influenza infection, and it is more common than most people realize. In clinical literature, the phenomenon is usually called “biphasic fever,” and studies in children treated with antivirals have found it in roughly 10 to 40 percent of cases depending on the flu strain involved. The pattern can be alarming, but the science behind it points to a mix of immune timing, viral biology, and sometimes the antivirals themselves.
What Biphasic Fever Looks Like
Clinicians define biphasic fever as a temperature that drops below a threshold (typically 37.5 °C or about 99.5 °F) for at least 24 hours and then spikes again. That second surge is what patients experience as “rebound.” It can feel like getting the flu all over again, complete with renewed fatigue, body aches, and sometimes cough. The second wave tends to be shorter and milder than the first, though not always.
The important distinction is between a symptom rebound and a viral rebound. Symptom rebound means you feel worse again; viral rebound means the virus itself is measurably increasing in your body after it had been declining. These two things often travel together, but not always. One study tracking viral loads in children treated with oseltamivir found no evidence of viral rebound once the virus had been fully cleared, even when some children still experienced returning symptoms.1The Pediatric Infectious Disease Journal. Virus Load Kinetics and Resistance Development During Oseltamivir Treatment in Infants and Children Infected With Influenza A(H1N1) 2009 and Influenza B Viruses In other words, the immune system can produce a second round of inflammatory symptoms while mopping up the remnants of an infection the virus is already losing.
How Often It Happens
Rates of flu rebound vary considerably depending on the virus type and the season. A Japanese study of children treated with oseltamivir across two flu seasons found that biphasic fever was far more common with influenza B than with influenza A. In the 2002–2003 season, about 20 percent of children with type B flu experienced biphasic fever, compared with 12 percent of those with the A/H3N2 strain. In the 2004–2005 season, the gap widened dramatically: 43 percent of type B cases had a second fever spike versus roughly 12 percent of A/H3N2 cases.2PubMed. The course of fever following influenza virus infection in children treated with oseltamivir
Children tend to experience biphasic fever more often than adults, likely because their immune systems mount a more vigorous inflammatory response. But rebound is not exclusive to kids. A prospective study that tracked viral shedding in hospitalized patients of various ages found viral rebound in about 6 percent of influenza patients, compared with about 13 percent of COVID-19 patients in the same cohort.3The Journal of Infectious Diseases. Disparate Kinetics of Viable Virus Shedding in Immunocompromised Patients: SARS-CoV-2 Versus Influenza Virus—A Prospective Real-World Cohort Study All patients who experienced viral rebound in that study eventually cleared the virus on their own.
Why Fever Comes Back
To understand rebound, it helps to know how the immune system fights flu in two phases. Before about day five of infection, your innate immune response is doing most of the heavy lifting, killing infected cells and mopping up loose virus relatively slowly. After day five, the adaptive immune response kicks in, and the pace changes dramatically. In mouse models, the half-life of infected airway cells drops from about 1.2 days during the innate phase to roughly half a day once adaptive immunity arrives. The half-life of free virus particles plummets from about four hours to under two minutes.4PubMed Central. Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus
That transition from innate to adaptive immunity is not always seamless. There can be a gap where the initial inflammatory response is winding down but the adaptive response has not yet fully mobilized. During that window, virus that was being suppressed can briefly expand again, or the surge of adaptive immune cells arriving at once can trigger a fresh wave of inflammation. Either scenario registers as renewed fever and worsening symptoms. The patient feels better, then worse, then better for good as the adaptive response takes full control.
How Antivirals Fit Into the Picture
Antivirals like oseltamivir (Tamiflu) and baloxavir (Xofluza) work through different mechanisms, and those differences matter for understanding rebound. Oseltamivir blocks neuraminidase, the enzyme the virus uses to release new copies from an infected cell. It does not stop cells from getting infected in the first place. Baloxavir, by contrast, targets the endonuclease that the virus needs to copy its genetic material inside a cell, preventing the virus from producing new copies at a very early stage of replication.
A mathematical modeling study explored how these different strategies affect the odds of rebound. The key finding: antivirals that block virus production, rather than preventing new cells from being infected, are more likely to cause rebound if the treatment course is not long enough. Because cells continue to become infected during treatment, those cells are essentially primed to start churning out virus the moment the drug is removed. Antivirals that prevent cells from becoming infected in the first place carry a lower rebound risk because fewer cells are loaded with virus when you stop taking the drug.5SpringerLink / Interdisciplinary Sciences: Computational Life Sciences. Viral Rebound After Antiviral Treatment: A Mathematical Modeling Study of the Role of Antiviral Mechanism of Action
This distinction has practical implications. Oseltamivir’s standard five-day course was designed to cover most of the window when new cells are actively being infected, but in some patients the viral lifecycle may outlast the prescription. Stopping the drug early or starting it late could both contribute to a rebound scenario.
Baloxavir and the Resistance Problem
Baloxavir brought its own rebound wrinkle when it was introduced. Because it is taken as a single dose, there is no multi-day treatment course to cut short. But a subset of patients develop resistance mutations, most commonly a substitution at position 38 in the virus’s polymerase acid protein, where isoleucine is replaced by threonine (often written as I38T in clinical reports). This mutation reduces the virus’s sensitivity to baloxavir.6The Journal of Infectious Diseases. Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains
In children, this has been linked to a clinical pattern that looks a lot like rebound. The drug suppresses the original virus rapidly, fever drops, and the patient feels better. But if a resistant variant emerges, it can replicate freely once the drug’s effect wanes, producing a second wave of symptoms. One study tracking children treated with baloxavir documented cases where fever cleared and then returned, with the second wave associated with detection of variant viruses carrying substitutions in the polymerase acid subunit.7Antiviral Research. Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018–2019 season and detection of variant influenza a viruses with polymerase acidic subunit substitutions The resistant virus replicates more slowly than the original at first, but it has the run of the field once the drug clears.
This is distinct from the immune-mediated rebound described above. With baloxavir resistance, the virus itself is genuinely bouncing back, not just the immune-driven symptoms. The clinical result for the patient feels the same, but the underlying biology matters for treatment decisions.
When It Is Not Really Rebound
A second wave of fever after flu can also signal something more serious than the virus itself coming back: a secondary bacterial infection. This is the classic scenario textbooks warn about, and it has a different timeline and different management needs.
Secondary bacterial pneumonia after influenza comes in two forms. Combined viral-bacterial pneumonia develops while the flu is still active, with bacteria taking advantage of damaged airways. Post-influenza pneumonia arrives after the virus is largely cleared, exploiting the weakened state of the lungs.8PubMed Central. Bench-to-bedside review: bacterial pneumonia with influenza – pathogenesis and clinical implications The second form is the one most likely to be confused with flu rebound, because the patient has already started feeling better before the bacterial infection takes hold.
Animal research has shown that bacterial co-infection can actually boost the flu virus itself. In mice infected with influenza and then exposed to Streptococcus pneumoniae, researchers observed a second peak in viral levels driven by the bacterial presence, with viral loads increasing by a factor of two to three above what they would have been without the bacteria.9PLoS Pathogens. Kinetics of Coinfection with Influenza A Virus and Streptococcus pneumoniae In these cases, the returning fever is not just from the bacteria or just from the flu: the two infections are amplifying each other.
The practical red flags for secondary infection rather than simple rebound include fever returning after three or more days of feeling well (rather than just one to two days), new or worsening productive cough, chest pain, or shortness of breath that was not present during the initial flu episode. If any of those appear, it is worth seeing a doctor promptly rather than waiting it out.
Who Is Most at Risk for Prolonged or Recurring Symptoms
Certain groups are more vulnerable to flu complications in general, and that includes a higher chance of prolonged or recurring symptoms. People with weakened immune systems, whether from HIV, organ transplants, stem-cell transplants, or medications that suppress immunity, face a distinct set of challenges. Their immune systems may struggle to mount the adaptive response that normally stamps out the virus after the first week.10PubMed Central. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses
In transplant recipients specifically, flu is associated with prolonged viral shedding, meaning the virus remains detectable for weeks rather than the typical seven to ten days. That extended shedding increases the window for both true viral rebound and secondary infections. These patients also face higher rates of bacterial and fungal superinfections on top of the flu, as well as risks to the transplanted organ itself.11PubMed Central. Influenza prevention and treatment in transplant recipients and immunocompromised hosts For immunocompromised patients, what looks like rebound may actually be flu that never fully cleared in the first place, simmering at low levels and flaring when conditions shift.
Flu Rebound Versus COVID Rebound
The concept of “rebound” entered mainstream conversation largely because of Paxlovid rebound during the COVID-19 pandemic, where patients would test negative and feel better, only to test positive again days later. That phenomenon generated headlines and confusion, but it is worth knowing that rebound is not unique to either COVID or flu.
A large study comparing COVID patients treated with Paxlovid and Molnupiravir found that rebound in infections, symptoms, and hospitalizations occurred with both drugs, with no significant difference in rebound rates between them. This suggested that COVID rebound was not simply a quirk of Paxlovid’s mechanism but a broader feature of how short antiviral courses interact with the immune response.12PubMed Central. COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022
The mathematical modeling insight described earlier applies here too: any antiviral that blocks virus production but does not prevent new cells from being infected creates conditions where rebound is possible if treatment ends before the immune system is ready to take over.5SpringerLink / Interdisciplinary Sciences: Computational Life Sciences. Viral Rebound After Antiviral Treatment: A Mathematical Modeling Study of the Role of Antiviral Mechanism of Action The common thread across flu and COVID rebound is that antivirals buy the immune system time, and when that purchased time is not enough, the virus can surge before adaptive immunity finishes the job. The lesson from both diseases is the same: rebound is typically self-limiting, but it signals that the antiviral-to-immunity handoff did not go smoothly.
Managing Flu Rebound at Home
If you start feeling worse again a day or two after improving, the first question is whether your symptoms are the same ones you had before. Returning fever, body aches, and fatigue that mirror the original flu episode are consistent with benign rebound. New symptoms, especially a worsening cough producing colored sputum, chest tightness, or difficulty breathing, should prompt a call to your doctor to rule out bacterial superinfection.
For straightforward rebound, management is essentially the same as for the original flu: rest, fluids, and over-the-counter fever reducers. There is generally no indication to start a second course of antivirals for garden-variety biphasic fever. The immune system is already ramping up its adaptive response, and the returning symptoms are often a sign that response is peaking rather than failing. Restarting oseltamivir is sometimes considered in immunocompromised patients with documented prolonged viral shedding, but that is a decision for a physician who can weigh the patient’s specific immune status.
One practical point that often gets missed: even during the “better” period between fever spikes, you may still be shedding virus and capable of infecting others. Standard guidance to stay home until you have been fever-free for at least 24 hours without medication still applies, and if fever returns, the clock resets. People often feel well enough during that gap to resume normal activities, which can spread the virus at a moment when the patient’s own defenses are between shifts.
When Sequential Respiratory Infections Muddy the Waters
Another scenario that can mimic flu rebound is catching a second respiratory virus shortly after the first. During any given winter, influenza, RSV, and various other respiratory viruses circulate simultaneously. Getting one does not make you immune to the others, and in some cases the first infection can alter your response to the second in unexpected ways.
Animal research on sequential RSV and influenza infections found that the order matters. Mice infected with RSV first and then exposed to influenza experienced less severe disease than mice given influenza alone. But the reverse sequence, flu followed by RSV, offered no such protection.13PubMed Central. Respiratory syncytial virus provides protection against a subsequent influenza A virus infection For a patient at home, the practical takeaway is that a “second wave” of illness two or more weeks after a flu diagnosis could be an entirely different infection rather than the original flu bouncing back. If you test negative for flu during the second episode, that is the likely explanation.
Rapid at-home flu tests and multi-pathogen tests available at pharmacies have made it easier to distinguish between these scenarios, though their sensitivity is imperfect, especially later in an illness when viral loads are lower. A point-of-care quantitative test tracked in one clinical study showed that patients typically turned negative by a median of eight days from symptom onset, and no cases of viral rebound were detected in that cohort.14PLOS ONE. Quantitative Influenza Follow-Up Testing (QIFT)—A Novel Biomarker for the Monitoring of Disease Activity at the Point-of-Care A positive test during a rebound episode confirms the flu is still active; a negative one points toward either post-infectious inflammation or a new pathogen.
Influenza B and the Rebound Gap
The outsized rebound rates seen with influenza B compared to influenza A deserve their own mention because the difference is large enough to affect how anxious you should be about a second fever spike. If you or your child has been diagnosed with type B flu, a return of fever is almost to be expected in certain seasons, as rates as high as 43 percent have been documented.2PubMed. The course of fever following influenza virus infection in children treated with oseltamivir Type B tends to cause a more protracted illness with a longer fever duration overall, and its immune evasion tactics differ from those of type A in ways that make the innate-to-adaptive handoff particularly bumpy.
From a practical standpoint, knowing which flu strain you have (which a doctor’s rapid test can distinguish) calibrates your expectations. A parent watching a child with type B flu bounce back to 39 °C on day four, after a day of feeling fine, is likely seeing normal biphasic fever rather than a treatment failure or a complication. For type A, the same pattern is less common and may warrant a closer look.